Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Disc Medicine, Inc. on June 18, 2026. The filing details the voting outcomes for three specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon and approved by the stockholders:
- Proposal 1: Election of Class III Directors
- Donald Nicholson, Ph.D.: Elected with 28,559,799 votes for (5,347,450 withheld).
- John Quisel, J.D., Ph.D.: Elected with 33,433,078 votes for (474,171 withheld).
- William White, M.P.P., J.D.: Elected with 33,355,406 votes for (551,843 withheld).
- All three directors were elected for a three-year term ending in 2029.
- Proposal 2: Advisory Vote on Executive Compensation
- Stockholders approved the compensation paid to Named Executive Officers on a non-binding, advisory basis.
- Result**: 33,528,449 votes for, 368,970 votes against, and 9,830 abstentions.
- Proposal 3: Ratification of Independent Auditor
- Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Result**: 35,908,900 votes for, 1,298 votes against, and 8,520 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the full biographical details and potential conflicts of interest for the newly elected Class III directors (Nicholson, Quisel, White) in the Definitive Proxy Statement filed on April 28, 2026.
- Review the specific compensation details for Named Executive Officers referenced in the Proxy Statement to understand the basis for the advisory vote approval.
- Confirm the scope of the audit engagement with Ernst & Young LLP for the fiscal year ending December 31, 2026.